Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. T. Stopeck
Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Sulindac and Sulindac Metabolites in Nipple Aspirate Fluid and Effect on Drug Targets in a Phase I Trial
Cancer Prevention Research
Medicine
Cancer Research
Oncology
Related publications
Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Phase I and Pharmacokinetic Study of 7-Hydroxystaurosporine and Carboplatin in Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
